Overcoming Cancer Tolerance with Immune Checkpoint Blockade

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Cancer Immunology

• Publication date

  2020-09-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-662-44946-2_6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer: A Phase 2 Clinical Trial

  2019cited by this paper
• Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

  2018cited by this paper
• Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

  2018cited by this paper
• Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer

  2018cited by this paper
• Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer

  2017cited by this paper
• TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action

  2017cited by this paper
• PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.

  2017cited by this paper
• Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

  2017cited by this paper
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  2017cited by this paper
• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

  2017cited by this paper
• Tim‐3 and its role in regulating anti‐tumor immunity

  2017cited by this paper
• Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

  2017cited by this paper
• Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

  2017cited by this paper
• Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

  2017cited by this paper
• Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

  2017cited by this paper
• Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

  2017cited by this paper
• First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer

  2017cited by this paper
• Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

  2017cited by this paper
• Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

  2017cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• Neoantigen landscape dynamics during human melanoma–T cell interactions

  2016cited by this paper
• Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

  2016cited by this paper
• Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

  2016cited by this paper
• Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

  2016cited by this paper
• Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

  2016cited by this paper
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Neocortical GABA release at high intracellular sodium and low extracellular calcium: an anti‐seizure mechanism

  2016cited by this paper
• Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

  2016cited by this paper
• TIM-3 Regulates Distinct Functions in Macrophages

  2016cited by this paper
• Adoptive T-Cell Therapy for Cancer.

  2016cited by this paper
• Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• Role of Genomic Instability in Immunotherapy with Checkpoint Inhibitors.

  2016cited by this paper
• Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

  2015cited by this paper
• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

  2015cited by this paper
• Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

  2014cited by this paper
• Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

  2014cited by this paper
• Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

  2014cited by this paper
• Immunomodulatory therapy for melanoma: ipilimumab and beyond.

  2013cited by this paper
• Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

  2013cited by this paper
• The role of "anti-inflammatory" cytokines in axon regeneration.

  2013cited by this paper
• Molecular Pathways Molecular Pathways : Coexpression of Immune Checkpoint Molecules : Signaling Pathways and Implications for Cancer Immunotherapy

  2013cited by this paper
• Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines

  2013cited by this paper
• Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

  2013cited by this paper
• Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

  2013cited by this paper
• PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.

  2013cited by this paper
• Hepatotoxicity with combination of vemurafenib and ipilimumab.

  2013cited by this paper
• Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

  2013cited by this paper
• Immunogenic cell death in cancer therapy.

  2013cited by this paper
• Immunotherapy for the Management of Advanced Melanoma: The Next Steps

  2013cited by this paper
• Agonistic CD40 Antibodies and Cancer Therapy

  2013cited by this paper
• A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

  2013cited by this paper
• Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma

  2013cited by this paper
• CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

  2013cited by this paper
• Coinhibitory molecules in cancer biology and therapy.

  2013cited by this paper
• Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

  2013cited by this paper
• Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

  2013cited by this paper
• Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

  2013cited by this paper
• A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

  2013cited by this paper
• Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

  2013cited by this paper
• Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer

  2013cited by this paper
• Endocrine side effects induced by immune checkpoint inhibitors.

  2013cited by this paper
• Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control

  2013cited by this paper
• Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

  2013cited by this paper
• Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity.

  2013cited by this paper
• The potential beneficial effects of drugs on the immune response to vaccination.

  2012cited by this paper
• Abscopal effect in a patient with melanoma.

  2012cited by this paper
• Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

  2012cited by this paper
• Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

  2012cited by this paper
• Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• New Insights on OX40 in the Control of T Cell Immunity and Immune Tolerance In Vivo

  2012cited by this paper
• Deleterious Effect of CTLA4‐Ig on a Treg‐Dependent Transplant Model

  2012cited by this paper
• Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.

  2012cited by this paper
• Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

  2012cited by this paper
• Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• When progressive disease does not mean treatment failure: reconsidering the criteria for progression.

  2012cited by this paper
• CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Epidemiology and management of uveal melanoma.

  2012cited by this paper
• Combination immunotherapy approaches.

  2012cited by this paper
• Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

  2012cited by this paper
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  2012cited by this paper
• Management of immune-related adverse events and kinetics of response with ipilimumab.

  2012cited by this paper

• Successful treatment of advanced alveolar soft part sarcoma with camrelizumab combined with apatinib: a case report.

  2021cites this paper